2024 Miami Breast Cancer Conference
Oral SERDs Poised to Impact Treatment of Hormone Receptor–Positive Breast Cancer
Suppression of the estrogen receptor has proven to be an effective treatment for hormone receptor–positive breast cancer, but standard endocrine therapies have liabilities that are not limited to thei...
Optimizing the Management of DCIS
“Ductal carcinoma in situ (DCIS), once a rare entity, now comprises 20% to 30% of newly diagnosed breast cancers detected on mammography and is appreciated to be a widely heterogeneous disease,” said...
Novel Approaches Show Early Activity in Endocrine-Resistant Breast Cancer
For breast cancer that is estrogen receptor–positive, CDK4/6 inhibitors, given with endocrine therapy, have become the standard of care, especially in metastatic disease. However, resistance to both e...
Can Artificial Intelligence Predict Treatment Response and Outcomes in Breast Cancer?
Artificial intelligence (AI)—computational analytics with routine imaging via radiology or pathology—can advance precision medicine in breast cancer, specifically by predicting response to therapy an...
